Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.

Diamant M, Van Gaal L, Stranks S, Guerci B, MacConell L, Haber H, Scism-Bacon J, Trautmann M

Diabetes care22 Feb 2012Cited by 69 (Europe PMC)

PMID22357185PMCIDPMC3308312DOI10.2337/dc11-1233PepBankPUB-22357185

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, once-weekly exenatide reduced A1C more than insulin glargine at 84 weeks.
In plain wordsIn patients with diabetes, weekly exenatide reduced A1C more than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C change
Study
n = 390
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
A1C change
−1.2%
EQW, 84 weeks
A1C change
−1%
IG, 84 weeks
Source sentences
Summary
At 84 weeks, A1C decreased from baseline (8.3%) by -1.2% for EQW vs. -1.0% for IG (P = 0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718501
02HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, A1C below 7.0% occurred in 44.6% with exenatide versus 36.8% with glargine, without significant difference.
In plain wordsIn patients with diabetes, rates of A1C below 7.0% did not differ significantly between weekly exenatide and glargine.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeA1C below 7.0%
Study
n = 390
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Patients with A1C <7.0%
44.6%
EQW
Patients with A1C <7.0%
36.8%
IG
Source sentences
Summary
The proportions of patients who achieved end point A1C targets <7.0 and ≤6.5% were 44.6% for EQW patients vs. 36.8% for IG patients (P = 0.084) and 31.3% for EQW patients vs. 20.2% for IG patients (P = 0.009), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718502
03HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, more exenatide patients achieved A1C at most 6.5% than glargine patients.
In plain wordsIn patients with diabetes, more weekly exenatide patients reached A1C at most 6.5% than glargine patients.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseA1C at most 6.5%
Study
n = 390
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Patients with A1C <=6.5%
31.3%
EQW
Patients with A1C <=6.5%
20.2%
IG
Source sentences
Summary
The proportions of patients who achieved end point A1C targets <7.0 and ≤6.5% were 44.6% for EQW patients vs. 36.8% for IG patients (P = 0.084) and 31.3% for EQW patients vs. 20.2% for IG patients (P = 0.009), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718503
04HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, exenatide reduced weight by 2.1 kg while glargine increased weight by 2.4 kg.
In plain wordsIn patients with diabetes, weight decreased with weekly exenatide and increased with glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 390
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Body weight change
−2.1 kg
EQW
Body weight change
2.4 kg
IG
Source sentences
Summary
Patients taking EQW lost 2.1 kg of body weight, whereas those taking IG gained 2.4 kg (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718504
05HumanRandomized controlled trialSafety outcome
In patients with diabetes, diarrhea occurred more often with exenatide than glargine, 12% versus 6%.
In plain wordsIn patients with diabetes, diarrhea occurred more often with weekly exenatide than glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDiarrhea
Study
n = 390
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Diarrhea incidence
12%
EQW
Diarrhea incidence
6%
IG
Source sentences
Summary
Among adverse events occurring in ≥5% of patients, diarrhea and nausea occurred more frequently (P < 0.05) in the EQW group than in the IG group (12 vs. 6% and 15 vs. 1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718507
06HumanRandomized controlled trialSafety outcome
In patients with diabetes, nausea occurred more often with exenatide than glargine, 15% versus 1%.
In plain wordsIn patients with diabetes, nausea occurred more often with weekly exenatide than glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n = 390
Comparator
Insulin glargine
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Nausea incidence
15%
EQW
Nausea incidence
1%
IG
Source sentences
Summary
Among adverse events occurring in ≥5% of patients, diarrhea and nausea occurred more frequently (P < 0.05) in the EQW group than in the IG group (12 vs. 6% and 15 vs. 1%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718508
07HumanRandomized controlled trialSafety outcome
In patients taking metformin and sulfonylurea, minor hypoglycemia occurred in 24% with exenatide versus 54% with glargine.
In plain wordsIn patients taking metformin and sulfonylurea, minor low blood sugar occurred less often with weekly exenatide than glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMinor hypoglycemia with metformin and sulfonylurea
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Minor hypoglycemia incidence
24%
EQW, metformin plus sulfonylurea
Minor hypoglycemia incidence
54%
IG, metformin plus sulfonylurea
Source sentences
Summary
Among patients taking metformin plus sulfonylurea, the incidence of minor hypoglycemia was 24% for EQW patients vs. 54% for IG patients (P < 0.001); among patients taking metformin alone, it was 8% for EQW patients vs. 32% for IG patients (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718505
08HumanRandomized controlled trialSafety outcome
In patients taking metformin alone, minor hypoglycemia occurred in 8% with exenatide versus 32% with glargine.
In plain wordsIn patients taking metformin alone, minor low blood sugar occurred less often with weekly exenatide than glargine.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMinor hypoglycemia with metformin alone
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 84 weeksAs given in this study (human).
Measurements
Minor hypoglycemia incidence
8%
EQW, metformin alone
Minor hypoglycemia incidence
32%
IG, metformin alone
Source sentences
Summary
Among patients taking metformin plus sulfonylurea, the incidence of minor hypoglycemia was 24% for EQW patients vs. 54% for IG patients (P < 0.001); among patients taking metformin alone, it was 8% for EQW patients vs. 32% for IG patients (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This 84-week extension study assessed the long-term safety and efficacy of EQW versus IG.
Summary · context
This multicenter, open-label, randomized, two-arm, parallel trial assessed change in A1C, proportions of patients achieving A1C <7.0 and ≤6.5%, body weight, incidence of hypoglycemia, and overall safety.
Report a problemFND-2235718506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00641056

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

AstraZenecan = 467Apr 2008 to Nov 2009

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 15 Jun 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.